OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the…
Browsing: Bristol-Myers Squibb
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.